dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Demetri, G. D. |
dc.contributor.author | Antonescu, C. R. |
dc.contributor.author | Bjerkehagen, B. |
dc.contributor.author | Bovée, J. V. M. G. |
dc.contributor.author | Boye, K. |
dc.contributor.author | Chacón, M. |
dc.contributor.author | Serrano Garcia, César |
dc.contributor.author | Valverde Morales, Claudia Maria |
dc.date.accessioned | 2021-10-01T08:06:10Z |
dc.date.available | 2021-10-01T08:06:10Z |
dc.date.issued | 2020-11 |
dc.identifier.citation | Demetri GD, Antonescu CR, Bjerkehagen B, Bovée JVMG, Boye K, Chacón M, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020 Nov;31(11):1506–17. |
dc.identifier.issn | 0923-7534 |
dc.identifier.uri | https://hdl.handle.net/11351/6371 |
dc.description | Entrectinib; Larotrectinib; Sarcoma |
dc.description.sponsorship | GDD was supported in part by the Ludwig Center at Harvard; the Dr Miriam and Sheldon G. Adelson Medical Research Foundation; and the Pan Mass Challenge (no grant numbers). IMS is supported by the National Institutes of Health/National Cancer Institute (grant number K08 CA241085). JYB was supported by NetSARC (INCA & DGOS) and RREPS (INCA & DGOS), RESOS (INCA & DGOS), EURACAN (EC 739521), LYRICAN (INCA-DGOS-INSERM 12563), LabEx DEvweCAN (ANR-10-LABX-0061), Institut Convergence PLASCAN (17-CONV-0002), RHU4 DEPGYN (ANR-18-RHUS-0009). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Annals of Oncology;31(11) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Sarcoma - Tractament |
dc.subject | Proteïnes quinases - Inhibidors |
dc.subject.mesh | Sarcoma |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Protein Kinase Inhibitors |
dc.title | Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.annonc.2020.08.2232 |
dc.subject.decs | sarcoma |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inhibidores de proteínas cinasas |
dc.relation.publishversion | https://doi.org/10.1016/j.annonc.2020.08.2232 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Demetri GD] Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, USA. [Antonescu CR] Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA. [Bjerkehagen B] Department of Pathology, Oslo University Hospital, Oslo, Norway. [Bovée JVMG] Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. [Boye K] Department of Oncology, Oslo University Hospital, Oslo, Norway. [Chacón M] Oncology Service Chair, Instituto Alexander Fleming, Buenos Aires, Argentina. [Serrano C] Sarcoma Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Valverde C] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 32891793 |
dc.identifier.wos | 000582637200010 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |